Advertisement
Organisation › Details
Jerini AG (FSE: JI4)
Jerini AG is a pharmaceutical company based in Berlin, Germany focusing on the discovery and development of peptide-based drugs. Having recognized the potential of peptides as natural starting molecules for drug discovery, the company has developed state-of-the-art technologies to identify and transform peptides into drugs. The company's lead product, Icatibant, is currently in Phase III clinical trials for the treatment of hereditary angioedema (HAE). It is estimated that between 1:10,000 and 1:50,000 people worldwide are affected with this disease. Based on its technology platform, Jerini has established several in-house development programs, which address indications within ophthalmology, oncology, and inflammatory therapeutic areas. The most advanced of these programs targets age-related macular degeneration (AMD), the leading cause of vision loss and blindness in people over the age of 55 in developed countries. *
Start | 1994-01-01 established_pre | |
Group | Takeda (Group) | |
Predecessor | Jerini Bio Tools GmbH | |
Industry | BIOTECH | |
Region | Berlin | |
Country | Germany | |
Street | 130 Invalidenstr. | |
City | 10115 Berlin | |
Tel | +49-30-97893-0 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2005-04-20) |
Currency | EUR | |
Annual sales | 13,124,000 (revenues, total, consolidated (2006) 2006-12-31) | |
Profit | -22,909,000 (2006-12-31) | |
Cash | 53,700,000 (2007-06-30) | |
* Document for »About Section«: | ||
Record changed: 2023-12-30 |
Advertisement
More documents for Takeda (Group)
- [1] T-Curx GmbH. (8/28/23). "Press Release: T-Curx GmbH Announces Appointment of Two Industry Leaders to Its Board of Directors"....
- [2] Fresenius Medical Care AG & Co. KGaA. (12/5/22). "Press Release: Helen Giza to Take Over as Chief Executive Officer of Fresenius Medical Care"....
- [3] VectorY B.V.. (11/8/22). "Press Release: VectorY Appoints Sander van Deventer as CEO and Makes Key Appointments to Its Leadership Team". Amsterdam....
- [4] Heidelberg Pharma AG. (9/9/22). "Press Release: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate". Ladenburg....
- [5] Takeda Pharmaceutical Co. Ltd.. (2/3/22). "Press Release: Takeda Announces Strategic Leadership Changes to Help Drive Continued Growth and Competitiveness in Global Marketplace". Osaka & Cambridge, MA....
- [6] Takeda Pharmaceutical Co. Ltd.. (1/10/22). "Press Release: Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (gd) T Cell Engager Therapies Targeting Solid Tumors". Osaka & London....
- [7] Integra Thepeutics S.L.. (12/2/21). "Press Release: Integra Tx Secures €4.5 Million in Funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures". Barcelona....
- [8] GammaDelta Therapeutics Ltd.. (10/27/21). "Press Release: Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic gdT Cell Therapies Addressing Solid Tumors". Osaka & London....
- [9] Panekès Partners SGR S.p.A.. (9/27/21). "Press Release: Panakès Partners Appoints Dr. Rob Woodman as Partner to Lead Biotech Investment". Milan....
- [10] Transine Therapeutics Ltd.. (6/2/21). "Press Release: Transine Therapeutics Closes Extended Seed Funding of £9.1 Million Co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund to Advance Its Novel Class of Therapeutic RNAs". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top